Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cavazzoni

Showing results (271-280 of 308) with videos related to

Pageof 31
Sort By:
Frontiers in Immunology|February 3, 2022
Characterization of Leptin Receptor<sup>+</sup> Stromal Cells in Lymph NodeLiwei Jiang, Mine Yilmaz, Mayuko Uehara, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2020
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patientsG Mazzaschi, R Minari, A Zecca, et al.
Oncotarget|April 9, 2026
Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolismClaudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Molecular Cancer|November 25, 2011
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell linesRoberta R Alfieri, Maricla Galetti, Stefano Tramonti, et al.
Oncotarget|December 2, 2017
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolismClaudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Cancer Letters|April 10, 2012
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clonesAndrea Cavazzoni, Mara A Bonelli, Claudia Fumarola, et al.
Cancer Drug Resistance (Alhambra, Calif.)|November 24, 2025
Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancerGeng Xu, Camilla Pecoraro, Mahrou Vahabi, et al.
JTO Clinical and Research Reports|February 24, 2022
<i>YES1</i> and <i>MYC</i> Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical ProofsRoberta Minari, Samuel Valentini, Denise Madeddu, et al.
Molecular Cancer Therapeutics|May 28, 2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene AlterationsMara A Bonelli, Andrea Cavazzoni, Francesca Saccani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating MutationSilvia La Monica, Denise Madeddu, Marcello Tiseo, et al.
Pageof 31

Showing results (271-280 of 308) with videos related to

Sort By:
Pageof 31
Frontiers in Immunology|February 3, 2022
Characterization of Leptin Receptor<sup>+</sup> Stromal Cells in Lymph NodeLiwei Jiang, Mine Yilmaz, Mayuko Uehara, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2020
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patientsG Mazzaschi, R Minari, A Zecca, et al.
Oncotarget|April 9, 2026
Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolismClaudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Molecular Cancer|November 25, 2011
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell linesRoberta R Alfieri, Maricla Galetti, Stefano Tramonti, et al.
Oncotarget|December 2, 2017
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolismClaudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Cancer Letters|April 10, 2012
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clonesAndrea Cavazzoni, Mara A Bonelli, Claudia Fumarola, et al.
Cancer Drug Resistance (Alhambra, Calif.)|November 24, 2025
Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancerGeng Xu, Camilla Pecoraro, Mahrou Vahabi, et al.
JTO Clinical and Research Reports|February 24, 2022
<i>YES1</i> and <i>MYC</i> Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical ProofsRoberta Minari, Samuel Valentini, Denise Madeddu, et al.
Molecular Cancer Therapeutics|May 28, 2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene AlterationsMara A Bonelli, Andrea Cavazzoni, Francesca Saccani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating MutationSilvia La Monica, Denise Madeddu, Marcello Tiseo, et al.
Pageof 31